|[May 22, 2014]
Research and Markets: Global Neuropathic Pain Report 2014: Hind Healthcare's Lidoderm/Versatis - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/xzjl6g/lidodermversatis)
has announced the addition of the "Lidoderm/Versatis
(Neuropathic Pain) - Forecast and Market Analysis to 2022"
report to their offering.
Lidoderm, the topical analgesic 5% lidocaine patch (medicated plaster),
was invented by US pharmacist Harry Hind (Hind Healthcare) and was
approved by the FDA in March 1999 for the treatment of PHN. Teikoku
Seiyaku then assumed from Hind full responsibility for manufacture of
the Lidoderm patch, while Endo Pharmaceuticals has the rights to market
the patch in the US. The patch was launched by Endo in the U in
September 1999 for the treatment of PHN. In Europe, the patch was
co-developed by Teikoku and the German drug company, Grünenthal, and was
launched in the EU in 2007 under the brand name Versatis.
Overview of Neuropathic pain, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Lidoderm including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Lidoderm for the top six countries from 2012 to
Sales information covered for the US, France, Germany, Italy, Spain
and the UK.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
Painful Diabetic Neuropathy
4 Disease Management
Treatment Overview and Guidelines
5 Competitive Assessment
For more information visit http://www.researchandmarkets.com/research/xzjl6g/lidodermversatis
[ Back To Telecom Signaling's Homepage ]